We’re seeing the same price setup in shares of small-cap biotech stock Bluebird Bio (BLUE) . It’s a bit of a misnomer to call Bluebird a small-cap stock After all, it wasn’t that long ago that this drug developer was actually well in mid-cap territory. But a 77% selloff in the last 12 months has changed the story there, and a descending triangle could spell even lower levels ahead.
